Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Absynth Biologics Ltd.

Vaccines and antibiotics against resistant infections

This article was originally published in Start Up

Executive Summary

Absynth Biologics Ltd. aims to harness patients’ own immune systems in the fight to prevent and treat bacterial infections; its platform identifies proteins on the cell membranes of bacteria that are essential for their survival, and are highly conserved. Combinations of these proteins, with additive or synergistic potential, are then used to create vaccines and antibodies that may inhibit bacterial activity, as well as engage the immune system to attack and eliminate the infection.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel